ACRSAclaris Therapeutics, Inc.
What is the market doing?
No clear lean: nothing decisive, though heavily shorted (+12% of shares).
Rangebound, no clear trend. Price is −17% vs its 200-day average.
Heavily shorted, settled Sep 30, 2026, about a week of normal trading to cover.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How ACRS is trading
Aclaris Therapeutics, Inc. is +66% over the past year while the S&P 500 is +16%: 50 points ahead of the market.
1-year return · S&P 500 +16%
- vs 200-day average
- −17%
vs 200-day average · a clear downtrend
- RSI (14)
- 40
RSI (14) · neutral
- Below its 52-week high
- 43%
Below its 52-week high
Details›
- Last close2026-10-23
- $3.75
- 1 monthS&P 500 −0.94%
- −30%
- 1 yearS&P 500 +16%
- +66%
- 5 yearsS&P 500 +86%
- −78%
- vs 50-day average$5.10
- −27%
- 52-week high
- $6.54
- 52-week low
- $2.13
- Annualised volatility
- 102%
- Insider selling, net, 6 monthsForms 3/4/5 to 2026-10-22
- $1.4M
| Year | Return |
|---|---|
| 2026 (year to date) | +25% |
| 2025 | +21% |
| 2024 | +136% |
| 2023 | −93% |
| 2022 | +8.3% |
| 2021 | +125% |
| 2020 | +242% |
| 2019 | −74% |
| 2018 | −70% |
| 2017 | −9.1% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 4 of 10 | +18% |
| Feb | 10 | 4 of 10 | −2.5% |
| Mar | 10 | 4 of 10 | −2.7% |
| Apr | 10 | 5 of 10 | +0.81% |
| May | 10 | 5 of 10 | −4.7% |
| Jun | 10 | 7 of 10 | +1.9% |
| Jul | 11 | 6 of 11 | +0.74% |
| Aug | 11 | 6 of 11 | −0.27% |
| Sep | 11 | 4 of 11 | +1.2% |
| Oct | 11 | 4 of 11 | +9.4% |
| Nov | 10 | 3 of 10 | +2.0% |
| Dec | 10 | 7 of 10 | +8.7% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.